Treatment of Erdheim-Chester Disease with Long-Term High-Dose Interferon-α

Seminars in Arthritis and Rheumatism

Volumn 41, Issue 6, 2012, Pages 907-913

  Hervier, Baptiste ^a,b   Arnaud, Laurent ^a,b,c   Charlotte, Frederic ^a,b   Wechsler, Bertrand ^a   Piette, Jean Charles ^a   Amoura, Zahir ^a,b,c   Haroche, Julien ^a,b  

^a PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^b SORBONNE UNIVERSITÉ   (France)

^c INSERM   (France)

Author keywords

Erdheim Chester disease; Histiocytosis; Interferon

Indexed keywords

ALPHA INTERFERON; CLADRIBINE; NATALIZUMAB; PEGINTERFERON ALPHA; PREDNISONE; SUNITINIB;

ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASTHENIA; BONE DISEASE; CAUSE OF DEATH; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INDICATION; DRUG MEGADOSE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; EAR NOSE THROAT DISEASE; ERDHEIM CHESTER DISEASE; EXOPHTHALMOS; FEMALE; FOLLOW UP; HEART DISEASE; HUMAN; HYPOPHYSIS DISEASE; LONG TERM CARE; LUNG DISEASE; MALE; MORTALITY; MYALGIA; PRIORITY JOURNAL; PRURITUS; REMISSION; RETROPERITONEAL FIBROSIS; SIDE EFFECT; SKIN DISEASE; THROMBOCYTOPENIA; VASCULAR DISEASE;

ADULT; AGED; ERDHEIM-CHESTER DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-ALPHA; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84861223869     PISSN: 00490172     EISSN: 1532866X     Source Type: Journal    
DOI: 10.1016/j.semarthrit.2011.11.004     Document Type: Article

References (38)

1. Chester W. Uber lipoidgranulomatose. Wirchows Arch Pathol Anat 2010, 279:561-602.
2. Stoppacciaro A., Ferrarini M., Salmaggi C., Colarossi C., Praderio L., Tresoldi M., et al. Immunohistochemical evidence of a cytokine and chemokine network in three patients with Erdheim-Chester disease: implications for pathogenesis. Arthritis Rheum 2006, 54:4018-4022.
3. Dion E., Graef C., Miquel A., Haroche J., Wechsler B., Amoura Z., et al. Bone involvement in Erdheim-Chester disease: imaging findings including periostitis and partial epiphyseal involvement. Radiology 2006, 238:632-639.
4. Arnaud L., Hervier B., Neel A., Hamidou M.A., Kahn J.E., Wechsler B., et al. CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients. Blood 2011, 117:2778-2782.
5. Haroche J., Amoura Z., Dion E., Wechsler B., Costedoat-Chalumeau N., Cacoub P., et al. Cardiovascular involvement, an overlooked feature of Erdheim-Chester disease: report of 6 new cases and a literature review. Medicine (Baltimore) 2004, 83:371-392.
6. Lachenal F., Cotton F., Desmurs-Clavel H., Haroche J., Taillia H., Magy N., et al. Neurological manifestations and neuroradiological presentation of Erdheim-Chester disease: report of 6 cases and systematic review of the literature. J Neurol 2006, 253:1267-1277.
7. Aouba A., Georgin-Lavialle S., Pagnoux C., Martin S.N., Renand A., Galateau-Salle F., et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010, 116(20):4070-4076.
8. Boissel N., Wechsler B., Leblond V. Treatment of refractory Erdheim-Chester disease with double autologous hematopoietic stem-cell transplantation. Ann Intern Med 2001, 135:844-845.
9. Bourke S.C., Nicholson A.G., Gibson G.J. Erdheim-Chester disease: pulmonary infiltration responding to cyclophosphamide and prednisolone. Thorax 2003, 58:1004-1005.
10. Braiteh F., Boxrud C., Esmaeli B., Kurzrock R. Successful treatment of Erdheim-Chester disease, a non-Langerhans-cell histiocytosis, with interferon-alpha. Blood 2005, 106:2992-2994.
11. Haroche J., Amoura Z., Trad S.G., Wechsler B., Cluzel P., Grenier P.A., et al. Variability in the efficacy of interferon-alpha in Erdheim-Chester disease by patient and site of involvement: results in eight patients. Arthritis Rheum 2006, 54:3330-3336.
12. Haroche J., Amoura Z., Charlotte F., Salvatierra J., Wechsler B., Graux C., et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008, 111:5413-5415.
13. Jendro M.C., Zeidler H., Rosenthal H., Haller H., Schwarz A. Improvement of Erdheim-Chester disease in two patients by sequential treatment with vinblastine and mycophenolate mofetil. Clin Rheumatol 2004, 23:52-56.
14. Mossetti G., Rendina D., Numis F.G., Somma P., Postiglione L., Nunziata V. Biochemical markers of bone turnover, serum levels of interleukin-6/interleukin-6 soluble receptor and bisphosphonate treatment in Erdheim-Chester disease. Clin Exp Rheumatol 2003, 21:232-236.
15. Myra C., Sloper L., Tighe P.J., McIntosh R.S., Stevens S.E., Gregson R.H., et al. Treatment of Erdheim-Chester disease with cladribine: a rational approach. Br J Ophthalmol 2004, 88:844-847.
16. Sheidow T.G., Nicolle D.A., Heathcote J.G. Erdheim-Chester disease: two cases of orbital involvement. Eye (Lond) 2000, 14(Pt. 4):606-612.
17. Smith J.R., Rosenbaum J.T. A role for methotrexate in the management of non-infectious orbital inflammatory disease. Br J Ophthalmol 2001, 85:1220-1224.
18. Arnaud L., Gorochov G., Charlotte F., Lvovschi V., Parizot C., Larsen M., et al. Systemic perturbation of cytokine and chemokine networks in Erdheim-Chester disease: a single-center series of 37 patients. Blood 2011, 117:2783-2790.
19. Jakobson A.M., Kreuger A., Hagberg H., Sundstrom C. Treatment of Langerhans cell histiocytosis with alpha-interferon. Lancet 1987, 2:1520-1521.
20. Lohr H.F., Godderz W., Wolfe T., Heike M., Knuth A., Meyer zum Buschenfelde K.H., et al. Long-term survival in a patient with Rosai-Dorfman disease treated with interferon-alpha. Eur J Cancer 1995, 31A:2427-2428.
21. Luft T., Pang K.C., Thomas E., Hertzog P., Hart D.N., Trapani J., et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J Immunol 1998, 161:1947-1953.
22. Luft T., Luetjens P., Hochrein H., Toy T., Masterman K.A., Rizkalla M., et al. IFN-alpha enhances CD40 ligand-mediated activation of immature monocyte-derived dendritic cells. Int Immunol 2002, 14:367-380.
23. Kirkwood J.M., Tarhini A.A. Adjuvant high-dose interferon-alpha therapy for high-risk melanoma. Forum (Genova) 2003, 13:127-140.
24. Wartelle-Bladou C., Arpurt J.P., Renou C., Pariente A., Pillon D., Nalet B., et al. High dose daily interferon-alpha induction and secondary adjunction of ribavirin in treatment-naive patients with chronic hepatitis C. A multicentric, randomised, controlled trial. Gastroenterol Clin Biol 2006, 30:525-532.
25. Jehn U., Heinemann V. Successful treatment of accelerated and blastic phase of chronic myeloid leukemia with high-dose interferon-alpha combined with hydroxyurea. Cancer Detect Prev 1998, 22:258-264.
26. Seeff L.B., Hoofnagle J.H. Appendix: The National Institutes of Health Consensus Development Conference Management of Hepatitis C 2002. Clin Liver Dis 2003, 7:261-287.
27. Reddy K.R., Wright T.L., Pockros P.J., Shiffman M., Everson G., Reindollar R., et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology 2001, 33:433-438.
28. Arnaud L., Malek Z., Archambaud F., Kas A., Toledano D., Drier A., et al. 18F-fluorodeoxyglucose-positron emission tomography scanning is more useful in followup than in the initial assessment of patients with Erdheim-Chester disease. Arthritis Rheum 2009, 60:3128-3138.
29. Brun A.L., Touitou-Gottenberg D., Haroche J., Toledano D., Cluzel P., Beigelman-Aubry C., et al. Erdheim-Chester disease: CT findings of thoracic involvement. Eur Radiol 2010, 20:2579-2587.
30. Haroche J., Cluzel P., Toledano D., Montalescot G., Touitou D., Grenier P.A., et al. Images in cardiovascular medicine. Cardiac involvement in Erdheim-Chester disease: magnetic resonance and computed tomographic scan imaging in a monocentric series of 37 patients. Circulation 2009, 119:e597-e598.
31. Drier A., Haroche J., Savatovsky J., Godeneche G., Dormont D., Chiras J., et al. Cerebral, facial, and orbital involvement in Erdheim-Chester disease: CT and MR imaging findings. Radiology 2010, 255:586-594.
32. Serratrice J., Granel B., De Roux C., Pellissier J.F., Swiader L., Bartoli J.M., et al. "Coated aorta": a new sign of Erdheim-Chester disease. J Rheumatol 2000, 27:1550-1553.
33. Betticher D.C., Lee S.M., Morris C., Clemons M., Thatcher N. Dacarbazine and interferon-alpha 2a in advanced malignant melanoma: high response rate and prolongation of response duration occur in different patient subpopulations. Melanoma Res 1995, 5:277-282.
34. Ferenci P., Brunner H., Laferl H., Scherzer T.M., Maieron A., Strasser M., et al. A randomized, prospective trial of ribavirin 400 mg/day versus 800 mg/day in combination with peginterferon alfa-2a in hepatitis C virus genotypes 2 and 3. Hepatology 2008, 47:1816-1823.
35. Rocha C.M., Perez R.M., Ferreira A.P., Carvalho-Filho R.J., Pace F.H., Silva I.S., et al. Efficacy and tolerance of interferon-alpha in the treatment of chronic hepatitis C in end-stage renal disease patients on hemodialysis. Liver Int 2006, 26:305-310.
36. Rustgi V.K., Esposito S., Hamzeh F.M., Shiffman M.L. Peginterferon alfa-2a/ribavirin in hepatitis C virus patients nontolerant or nonresponsive to peginterferon alfa-2b/ribavirin. Aliment Pharmacol Ther 2008, 27:433-440.
37. Schalm S.W., Weiland O., Hansen B.E., Milella M., Lai M.Y., Hollander A., et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999, 117:408-413.
38. Arnaud L., Pierre I., Beigelman-Aubry C., Capron F., Brun A.L., Rigolet A., et al. Pulmonary involvement in Erdheim-Chester disease: A single-center study of thirty-four patients and a review of the literature. Arthritis Rheum 2010, 62:3504-3512.